SS-31 Research: What the Studies Show
SS-31 — also known as elamipretide, Bendavia or MTP-131 — is one of the few mitochondrial-targeted peptides to reach large registrational human trials. The results are genuinely mixed, and the detail matters. Here is what each programme actually measured.
Mechanism of action
SS-31 is a cell-permeable tetrapeptide that concentrates in the inner mitochondrial membrane. It binds cardiolipin, the signature lipid that stabilises cristae architecture, organises the electron transport chain and keeps electron flow tight.
By stabilising cardiolipin-protein interfaces, the peptide is proposed to improve coupling efficiency in the electron transport chain and lower the leak of reactive oxygen species — rather than acting as a conventional free-radical scavenger.
The PNAS interactome work gave this a concrete molecular map: SS-31 nests into cardiolipin-protein interfaces and specifically stabilises two protein groups — those driving ATP production through the oxidative phosphorylation pathway (Complexes III, IV, and ATP Synthase) and those driving 2-oxoglutarate metabolic processes (TCA cycle).
The studies
SS-31 has an unusually honest evidence base: strong mechanism, strong preclinical data, and human trials that have repeatedly missed their primary endpoints while showing signals in secondary and long-term measures. Both sides are below.
Rare cardiolipin disease
TAZPOWER — elamipretide in Barth syndrome
Whether stabilising cardiolipin helps in a genetic disorder defined by cardiolipin deficiency — the cleanest possible test of the mechanism.
Double-blind, randomised crossover trial · 40 mg daily subcutaneous elamipretide · 12 weeks controlled phase · 168-week open-label extension · 6-minute walk test primary endpoint, cardiac imaging and fatigue secondary
- Not met
- Primary endpoint (12-week 6MWT)
- +>40%
- LV stroke volume (168-week extension)
- Improved long-term
- Fatigue tolerance
- The controlled 12-week phase did not improve the 6-minute walk test — the trial missed its primary endpoint, and that should be stated plainly.
- The 168-week open-label extension told a different story: durable cardiac improvement including a greater than 40% increase in left ventricular stroke volume, plus better fatigue tolerance.
- The likely lesson is timescale. Structural mitochondrial remodelling appears to need far longer than twelve weeks to show up in functional endpoints — but open-label extension data carries much weaker inference than the randomised phase.
Primary mitochondrial myopathy
MMPOWER — phase 1/2 dose-ranging in primary mitochondrial myopathy
Safety, tolerability and whether exercise capacity improves in patients with primary mitochondrial myopathy.
Multicentre, randomised, double-blind, placebo-controlled dose-escalation · short-course intravenous elamipretide · 6-minute walk test primary endpoint
- +64.5 m
- 6MWT — elamipretide
- +20.4 m
- 6MWT — placebo
- Class I
- Evidence grade
- Produced Class I evidence of clinical efficacy with a dose-dependent improvement in walking distance — a strong early result by the standards of this field.
- The treated group walked 64.5 m further versus 20.4 m on placebo, and tolerability was acceptable at the doses tested.
- This positive short-course result is what justified the much larger phase 3 programme below.
MMPOWER-3 — phase 3 confirmatory trial
Whether the phase 1/2 exercise-capacity signal reproduces in a large confirmatory population.
Multicentre, randomised, double-blind, placebo-controlled · 24 weeks daily subcutaneous elamipretide · 6-minute walk test and patient-reported fatigue co-primary endpoints
- Not met
- Primary endpoints
- Broad PMM cohort
- Population
- Generally tolerated
- Safety
- The phase 3 trial did not meet its primary efficacy endpoints across the overall population — the earlier signal did not reproduce at scale.
- This is the single most important counterweight to the enthusiasm around SS-31, and it is why the compound remains investigational.
- Post-hoc discussion has centred on whether primary mitochondrial myopathy is too genetically heterogeneous for a single functional endpoint to detect benefit, but that is a hypothesis, not a result.
Cardiovascular
PROGRESS-HF and cardiac translational work
Whether correcting mitochondrial dysfunction improves outcomes in structural heart failure.
Randomised clinical evaluation in heart failure alongside animal pressure-overload models · cardiac mitochondrial dynamics, myocardial fibrosis and Sirt3/OPA1 signalling endpoints
- Restored
- Preclinical cardiac mitochondrial dynamics
- Reduced
- Myocardial fibrosis (animal)
- Not met
- Human heart-failure endpoints
- Animal and preclinical models showed robust restoration of cardiac mitochondrial dynamics via Sirt3/OPA1 signalling, with reduced myocardial fibrosis.
- That did not translate: the human trial failed to achieve significant efficacy on heart-failure endpoints.
- A clear example of the translational gap in this field — strong mechanism and strong animal data are not sufficient evidence of human benefit.
Ageing, eye and kidney
ReCLAIM programme and age-related tissue studies
Whether SS-31 limits oxidative damage and structural decay in ageing tissue, particularly retina and kidney.
Clinical evaluation in age-related macular degeneration plus translational models of glomerular ageing · mitochondrial ultrastructure, senescence markers (p16, SA-β-gal), podocyte injury and capillary integrity endpoints
- Reversed
- Age-associated mitochondrial damage
- Reduced
- Senescence markers (p16, SA-β-gal)
- Improved
- Glomerular capillary integrity
- Reversed age-associated mitochondrial structural damage and lowered systemic cell-senescence markers p16 and SA-β-gal.
- Protected podocytes from injury and improved capillary integrity in glomerular architecture — the most concrete kidney-ageing data on the compound.
- This is the arm of the research most often cited in longevity contexts; note that the ageing endpoints here are largely biomarker and structural, not hard clinical outcomes.
Mechanism mapping
Mitochondrial protein interactome of SS-31 (PNAS)
Identifying exactly which mitochondrial proteins SS-31 physically interacts with.
Affinity-tagged chemical cross-linking coupled to mass spectrometry · mapping of SS-31 binding partners at cardiolipin-protein interfaces
- Cardiolipin-protein interfaces
- Binding site
- OXPHOS: Complex III, IV, ATP synthase
- Stabilised group 1
- 2-oxoglutarate / TCA enzymes
- Stabilised group 2
- Definitively showed that SS-31 nests directly into cardiolipin-protein interfaces rather than acting diffusely in the matrix.
- It specifically stabilises two protein groups: those driving ATP production through the oxidative phosphorylation pathway (Complexes III, IV, and ATP Synthase) and those driving 2-oxoglutarate metabolic processes (TCA cycle).
- This is the strongest part of the SS-31 evidence base — the mechanism is mapped at molecular resolution, even where the clinical endpoints have disappointed.
Storage & handling
SS-31 is supplied as a lyophilised powder. Keep sealed vials refrigerated or frozen, protected from light and moisture.
Reconstitute with bacteriostatic water directed slowly down the inner wall of the vial and swirl gently until clear. Do not shake.
Store reconstituted solution at 2-8 °C and use within the stability window set by your lab's standard operating procedures.
All information on this page is provided for laboratory and educational reference only. Peptides Lab SA (PTY) Ltd supplies compounds strictly for in-vitro research use. Nothing here is medical advice, a dosing recommendation, or a claim of human safety or efficacy.